The structure of electronic medical record data prevents easy population-level monitoring of hepatitis C virus (HCV) treatment uptake and cure. Using an HCV registry from a public hospital system in Atlanta, Georgia, we developed multiple algorithms that use serial HCV RNA test results as proxy measures for initiation of direct-acting antiviral (DAA) treatment and sustained virological response (SVR). We calculated sensitivity and positive predictive values (PPVs) by comparing the algorithms with the DAA initiation and SVR results from the registry. From December 2013 to August 2016, 1,807 persons actively infected with HCV were identified in the registry. Of those, 698 initiated DAA treatment on the basis of medical record abstraction; of 442 patients with treatment start and/or end dates, 314 had documented SVR. Treatment algorithm 2 (a detectable HCV RNA result followed by 2 sequential HCV RNA test results) and treatment algorithm 5 (a detectable HCV RNA result followed by 2 sequential HCV RNA test results >6 weeks apart) had the highest sensitivity (87% and 85%, respectively) and PPV (80% and 82%, respectively) combinations. Four SVR algorithms relied on fulfilling treatment algorithm definitions and having an undetectable HCV RNA test result ≥12 weeks after the last HCV RNA result; sensitivity for all 4 algorithms was 79%, and PPV was 92%-93%. Algorithms using serial quantitative HCV RNA results can serve as proxy measures for evaluating population-level DAA treatment and SVR outcomes.
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In the United States, hepatitis C virus (HCV) infection is a leading cause of liver-related death, cirrhosis, and hepatocellular carcinoma (1, 2) . An estimated 3.5 million persons are estimated to be infected with HCV in the United States; however, adults born during 1945-1965, often referred to as "baby boomers," have an estimated anti-HCV antibody prevalence of approximately 3%, which is 6 times higher than that of other adults (3, 4) . Historically, HCV treatments were used sparingly because of side effects and only modest efficacy; however, since 2013, safe, all-oral, interferon-free, tolerable, and curative direct-acting antiviral (DAA) therapies have become available (5) . As a result of these advances, the number of persons eligible for HCV treatment has increased (5), yet monitoring of the uptake of treatment and cure at a facility or population level can be challenging because these events may not be discreetly captured in an electronic medical record (EMR) system.
HCV cure cascades are a construct that have been used to conceptualize the monitoring of patients from diagnosis to cure using discreet steps in clinical care, such as HCV antibody testing, HCV RNA testing, HCV RNA positivity, initiation of HCV treatment, completion of HCV treatment, and cure. Although data from EMRs have been used to construct HCV cure cascades (6) (7) (8) , much of the data were extracted by manual chart review, which essentially treats an EMR as a copy of a paper-based record stored in electronic form rather than as a tool for monitoring public health. Automated data extraction from EMRs has been used to evaluate diabetes and asthma management, as well as to assist with public health surveillance (9-15); however, using these systems effectively can be challenging because of the unavailability of certain data, including treatment data, which may be found in unstructured data fields (11, 16) . It may be possible to overcome challenges like lack of treatment data if acceptable proxy measures can be identified to serve as indicators for specific outcomes, such as treatment initiation.
In the case of caring for and treating patients with HCV infection, health-care providers use the HCV RNA test result to diagnose active infection, monitor response to treatment, and determine cure, defined as a sustained virological response (SVR) 12 weeks after treatment completion (denoted SVR12) (5) . Therefore, we sought to develop algorithms using serial HCV RNA test results to serve as surrogate definitions for HCV treatment initiation and SVR12 for the purposes of monitoring treatment initiation and treatment outcomes in an HCV registry.
METHODS
We performed a secondary analysis using deidentified data collected from a demonstration project that piloted the use of an EMR to create a registry of HCV-infected patients in a large, urban safety-net health system in Atlanta, Georgia. For the creation of the registry, patient-level data from 2004-2016 were extracted from the EMR, including anti-HCV antibody results, HCV RNA and genotype test results, and HCV treatment regimens, through a combination of automated data extraction and manual chart review. These data were used to develop a cure cascade to follow patients from diagnosis to cure.
Our institution's institutional review board determined that this analysis was research but did not involve identifiable human subjects. The local institutional review board for the study site determined that the project was human subjects research but was exempt from institutional review board review.
The health system used in our study has a liver clinic staffed by internal medicine physicians who care for patients with active HCV infection. A typical patient in this system received HCV RNA testing at the following 5 time points: 1) prior to treatment initiation, to confirm active HCV infection; 2) 4 weeks after the start of DAA treatment; 3) treatment completion (usually 12 weeks after DAA start); 4) 12 weeks after DAA completion (the SVR12 time point); and 5) 24 weeks after DAA completion (the SVR24 time point). Therefore, the registry was designed to capture up to 5 of the most recent HCV RNA test results. Data collected on HCV RNA test results included the quantitative value of the test result and the test date. A viral load of ≥12 IU/mL was considered detectable and a viral load of <12 IU/mL was considered undetectable, since 12 IU/mL was the lower limit of detection and quantification using the Abbott Molecular m2000 RealTime System (Abbott Laboratories, Abbott Park, Illinois). For the purposes of the analysis, SVR was defined as an undetectable HCV RNA test result at the SVR12 time point and, if a test was performed, at the SVR24 time point.
We developed and evaluated multiple algorithms for either initiation of HCV treatment or SVR using serial HCV RNA test results. We evaluated 5 algorithms to predict initiation of HCV treatment, each beginning with an initial detectable HCV RNA test (initial test) result followed by: 1) 3 sequential HCV RNA test results at any time, regardless of test result; 2) 2 sequential HCV RNA test results at any time, regardless of test result; 3) 1 sequential HCV RNA test result at any time, regardless of test result; 4) 1 sequential HCV RNA test result at any time that indicated at least a 10-fold decrease in viral load compared with the initial test; and 5) 2 sequential HCV RNA test results >6 weeks apart, regardless of test result. We compared treatment algorithms with the treatment information documented in the registry. Registry data included the medication name and treatment start and end dates. Information on treatment regimen was automatically extracted from the patient's medication list and the EMR's drug usage report. Discrepancies in the treatment regimen from the automated data pull were corrected by manual chart review. We defined treatment for HCV as having initiated a noninterferon DAA regimen during the analytical time period (December 1, 2013-August 16, 2016). We limited the data set to only those persons with HCV RNA test results or treatment start dates after December 1, 2013, which was the approval month and year for sofosbuvir, the first all oral, non-interferon-based DAA treatment. Additionally, patients treated with interferon-containing regimens were excluded from the analysis.
We also evaluated 5 algorithms to predict SVR: 1) an undetectable HCV RNA test result ≥6 months after the first detectable HCV RNA test; 2) treatment initiation algorithm 2 (the initial test plus 2 sequential tests), followed by a final undetectable HCV RNA result ≥12 weeks later; 3) treatment initiation algorithm 3 (the initial test plus 1 sequential test), followed by a final undetectable HCV RNA result ≥12 weeks later; 4) treatment initiation algorithm 4 (the initial test plus a single sequential test with at least a 10-fold decrease in viral load), followed by a final undetectable HCV RNA result ≥12 weeks later; and 5) treatment initiation algorithm 5 (the initial test plus at least 2 sequential tests >6 weeks apart), followed by a final undetectable HCV RNA result ≥12 weeks later. We compared SVR algorithms with documented SVR in the registry. We defined SVR in the registry as an undetectable viral load ≥12 weeks after the date of treatment completion or, if treatment completion dates were missing, ≥24 weeks after the date of treatment initiation (at the time of data collection, 8-week DAA regimens were not being prescribed).
We determined the performance of each algorithm by calculating the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), comparing each algorithm classification with the DAA treatment initiation and SVR results from the registry as the gold standard. Using treatment algorithm 1, we calculated sensitivity, specificity, PPV, and NPV in the following manner: Logistic regression was used to calculate odds ratios and 95% confidence intervals for each algorithm. We evaluated the predictive accuracy of each algorithm by assessing the discrimination of each algorithm. Discrimination refers to the ability of an algorithm to distinguish between persons with and without the outcome (in this case, treatment for the treatment algorithms or SVR for the SVR algorithms) and was measured using the C statistic or area under the receiving operating characteristic curve. A C statistic of 0.5 demonstrates poor discrimination, while a C statistic of 1.0 means that the algorithm is able to perfectly distinguish between persons with and without the outcome. All analyses were conducted with SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
From December 2013 to August 2016, 1,807 persons actively infected with HCV were identified in the registry. Among those, the median age was 57 years (range, 18-89), 1,521 (84.2%) were born during 1945-1965, 1,203 (66.6%) were male, 1,499 (82.9%) were non-Hispanic black, 1,017 (56.3%) were publicly insured, 283 (15.7%) were uninsured, and 127 (7.0%) were coinfected with human immunodeficiency virus. After applying our inclusion criteria, we found that 698 patients had initiated treatment with a non-interferon-based DAA regimen since December 1, 2013 (Figure 1 ). Of those who initiated treatment with a non-interferonbased DAA regimen, 256 persons were missing data for both treatment start date and treatment end date and were thus excluded from the SVR analysis. Of the 442 persons who initiated treatment and had information on treatment start and/or end dates, 314 had a documented SVR, and these cases were used as the gold standard for our SVR algorithm. Table 1 lists the sensitivity, specificity, PPV, and NPV for algorithms for DAA treatment initiation. Using the example of algorithm 1, the sensitivity of 74% means that of all persons who received treatment (n = 698), 515 (74%) met the definition of the algorithm, so the algorithm was able to "successfully" identify treatment among 74% of all those treated. The specificity of 95% means that of all persons who did not receive treatment (n = 1,109), 95% (n = 1,059) did not meet the definition of the algorithm. The PPV of 91% means that of the persons who met the algorithm definition (n = 565), 91% (n = 515) were treated. Finally, the NPV of 85% means that of those who did not meet the algorithm definition (n = 1,242), 85% (n = 1,059) were not treated. For the 5 algorithms evaluating DAA treatment initiation, sensitivities ranged from 74% to 96%, specificities ranged from 57% to 95%, PPVs ranged from 58% to 91%, and NPVs ranged from 85% to 95%. Algorithm 3 (an initial detectable HCV RNA test result followed by 1 sequential HCV RNA test result at any time, regardless of test result) had the highest sensitivity (96%) but the lowest PPV (58%) for predicting the initiation of DAA therapy. Since algorithm 3 had the lowest PPV, its definition had the lowest odds ratio and 95% confidence interval for predicting treatment (odds ratio (OR) = 28.7, 95% confidence interval (CI): 19.7, 22.0). Algorithm 1 (an initial detectable HCV RNA test result followed by 3 sequential HCV RNA test results at any time, regardless of test result) had the lowest sensitivity (74%) but the highest PPV (91%) for predicting initiation of DAA therapy (OR = 59.6, 95% CI: 42.0, 82.9). Algorithm 3 had the lowest C statistic (C = 0.76), and all of the other treatment algorithms discriminated similarly well, with C statistics ranging from 0.84 to 0.87. Table 2 shows the sensitivity, specificity, PPV, and NPV for the algorithms for SVR. For the 5 algorithms evaluating SVR, sensitivities ranged from 79% to 83%, specificities ranged from 64% to 85%, PPVs ranged from 85% to 93%, and NPVs ranged from 61% to 62%. Algorithm 1 (an undetectable HCV RNA test result ≥6 months after the first detectable HCV RNA test result) had the highest sensitivity (83%) but the lowest PPV (85%) for SVR. Since algorithm 1 had the lowest PPV, its definition had the lowest odds ratio (OR = 8.8, 95% CI: 5.5, 14.0). The C statistic for the SVR definition for algorithm 1 was 0.74. Algorithms 2-5, which relied on meeting the definition of the treatment initiation algorithms, all had a sensitivity of 79% and similar PPVs (92%-93%). The odds ratios for algorithms 2-5 ranged from 17.5 to 21.1. The C statistics for SVR algorithms 2-5 ranged from 0.81 to 0.82.
DISCUSSION
Where key data such as treatment start and end dates and SVR are missing from EMRs, algorithms using serial HCV RNA test results as proxy markers may be a useful tool for monitoring the HCV cure cascade. Depending on the research or surveillance needs, the algorithms we developed can be applied to larger data sets to construct an HCV cure cascade while maintaining acceptable sensitivity and PPVs for predicting DAA treatment initiation and SVR.
Monitoring HCV-infected patients from diagnosis to cure requires multiple types of data, including laboratory results and treatment information that need to be considered comprehensively to define discrete steps in the cure cascade (7, 8) . HCV RNA test results are checked at multiple intervals to monitor response to treatment (5). Our analysis demonstrates that algorithms relying on serial HCV RNA test results alone can be applied to longitudinal EMR data to determine whether patients have initiated DAA treatment and achieved SVR with a high degree of certainty. Of the 5 algorithms evaluated to determine initiation of DAA treatment, sensitivities ranged from 74% to 96% and PPVs ranged from 58% to 91%. Three of the 5 treatment algorithms relied on an increasing number of RNA tests. Since HCV treatment monitoring typically involves checking RNA levels at several different time points (5), as expected, we found that increasing the number of RNA tests in the algorithm definition improved the PPV while decreasing the sensitivity of the algorithm. In terms of overall performance, we found that treatment algorithm 2 (an initial detectable HCV RNA test result followed by 2 sequential HCV RNA test results) and treatment algorithm 5 (an initial detectable HCV RNA test result followed by 2 sequential HCV RNA test results >6 weeks apart) had the best combination of sensitivity (87% and 85%, respectively) and PPVs (80% and 82%, respectively). The majority of the SVR algorithms relied on meeting the definition of one of the treatment algorithms. Regardless of which treatment algorithm was applied to the SVR algorithm, a high PPV (92%-93%) was found for each SVR algorithm based on the presence of an undetectable HCV RNA test result ≥12 weeks after the last HCV RNA test result. While the SVR algorithms had high PPVs, the sensitivity of the algorithms ranged from 79% to 83%, meaning that they misclassified nearly 20% of persons with documented SVR as "non-SVR." The primary reason for this was that misclassified individuals were missing an HCV RNA result or that a sufficient number of tests had been performed but they had occurred at "incorrect" intervals according to the algorithms. This highlights a limitation in the use of these algorithms in a "real-world" setting, where HCV-infected patients may not attend appointments at expected intervals.
Lattimore et al. (13) used a similar approach of applying serial HCV RNA tests to determine treatment rates in an English cohort of HCV-infected patients in the pre-DAA era. Similar to our algorithms employing time and repeat HCV RNA test results, Lattimore et al.'s algorithm considered people to have initiated therapy if they had a detectable HCV RNA test result and 3 or more sequential HCV RNA test results within a 390-day period (13) . People were considered to have achieved SVR if the final HCV RNA test result in the sequence was undetectable (13) . In testing the performance of the algorithm with data from the Trent HCV Study, they found that the algorithm was 95% sensitive and 93% specific for detecting treatment and 100% sensitive and 93% specific for detecting SVR (13) .
Although their algorithm appears to perform better than ours, it is important to consider that their algorithm was developed when interferon-based therapies were the mainstay of treatment; therefore, the results would not be applicable to 8-to 12-week DAA regimens. Because interferon-based therapies were longer in duration than DAA therapy and were associated with more adverse events, patients had more opportunities for monitoring and health-care encounters than in our population. These differences in health-care utilization may have increased the opportunities for laboratory testing, including HCV RNA testing while under treatment, which would have increased the probability of being identified per the parameter in their algorithm. A 12-week treatment period in the DAA era limits the number of health-care encounters a patient may have while on HCV treatment, so a missed encounter resulting in a missed HCV RNA test would have a higher likelihood of affecting the predictive accuracy of an algorithm relying on sequential HCV RNA testing or specified time intervals between tests.
HCV cure cascades have become important tools for evaluating access to care and HCV treatment outcomes and identifying barriers to care (6) (7) (8) . The observational data in previously described cascades have often relied on chart abstraction (6) (7) (8) . Although chart abstraction can yield high-quality data, it is resource-intensive and has limited scalability beyond the particular study period or participating institutions. Data from EMRs are appealing because they can create comprehensive, longitudinal records for health systems and can be extracted automatically. Although EMR data can be used to create disease registries, challenges such as missing data may limit the ability to use these tools. Treatment data in particular may be difficult to capture from an EMR, since information on filled prescriptions and treatment initiation dates may be missing or may not be accurately captured in an EMR system in an extractable format, particularly if the institution does not have an on-site pharmacy. If treatment information is unavailable from the EMR or through prescription claims data, algorithms such as ours can provide a means for using commonly available laboratory data to monitor trends in HCV treatment initiation and cure.
Our results are subject to limitations. First, we were unable to determine treatment start and end dates for a subset of patients, which resulted in their exclusion from the SVR analysis. This may have led to misclassification, as it is possible that the proportion of patients achieving SVR in this subset may have differed from that in our analytical population. However, assuming that those persons successfully completed therapy, our results probably underestimated the number of patients achieving SVR. Second, our registry only abstracted up to 5 HCV RNA test results, which may have resulted in misclassification of SVR results for patients with treatment regimens greater than 12 weeks in duration. Third, our analysis was limited to patients receiving care in a single health system. While this may limit the generalizability of our results to other health systems that may have differing protocols for monitoring patients while on HCV therapy, these algorithms may be tailored and applied to a specific health system. Finally, our algorithms were not validated in an external cohort, and it is possible that the performance of the algorithms may differ if applied to data from other health-care facilities. We provided the results of several algorithms so that they can be further validated in other real-world clinical settings.
Algorithms relying on serial HCV RNA tests can be used as a proxy for determining initiation of DAA treatment and achievement of SVR in longitudinal data from an HCV registry where treatment data are unavailable. These algorithms can serve as a useful tool for population health and health services research using EMR data to create HCV cure cascades while obviating the need to perform manual chart review. Although additional validation of these algorithms will be needed, they have the potential to be a powerful tool in monitoring secular trends in HCV treatment and cure.
